5KW.F Stock Analysis
5K
Uncovered
SkinBioTherapeutics PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.032
Dividend yield
—
Shares outstanding
173.14 B
SkinBioTherapeutics Plc is a life science company, which focuses on skin health. The company is headquartered in Newcastle Upon Tyne, Northumberland and currently employs 12 full-time employees. The company went IPO on 2017-04-05. The principal activity of the Company and its subsidiaries is the identification and development of technology that harnesses the human microbiome to improve health. The firm's platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The firm is targeting five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. The firm's product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis. The firm is also focused on the application of the SkinBiotix technology in the treatment of various classes of skin wounds.